Shire Plc"s second-quarter revenue sank by 19 percent as the company faced generic competition of its hyperactivity pill, Adderall [amphetamine and dextroamphetamine] in April. Products for attention deficit hyperactivity disorder account for about half of Shire"s 2008 revenue. The company tried to switch patients to Vyvanse [lisdexamfetamine] before Adderal lost patent protection. Shire may supply its treatment for Gaucher disease velaglucerase alfa because supplies of Genzyme"s Cerezyme [imiglucerase], the only other drug for the disease, has been delayed due to manufacturing issues. Vela met its goals in phase three trials so FDA has agreed it can be supplied to patients ahead of formal approval. Shire has approached the FDA about bringing its Fabry disease drug, Replagal (agalsidase alfa) to the US due to shortages of Genzyme Corp."s Fabrazyme (agalsidase beta).
저작권자 © 메디칼업저버 무단전재 및 재배포 금지